• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    OpGen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8/15/24 4:39:45 PM ET
    $OPGN
    Medical Specialities
    Health Care
    Get the next $OPGN alert in real time by email
    false 0001293818 0001293818 2024-08-09 2024-08-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    August 9, 2024
    Date of Report (date of earliest event reported)

     

     

     

    OpGen, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware

     

    001-37367

     

    06-1614015

    (State or other jurisdiction of
    incorporation or organization)
      (Commission
    File Number)
     

    (I.R.S. Employer
    Identification Number)

     

    23219 Stringtown Road, Suite 300
    Clarksburg, MD 20871
    (Address of principal executive offices)(Zip code)

     

    (240) 813-1260
    (Registrant’s telephone number, including area code)

     

    Not Applicable
    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   OPGN   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On August 9, 2024, the Board of Directors (the “Board”) of OpGen, Inc. (the “Company”) voted to appoint Christian-Laurent Bonte, Victor Chua Kok Hoe, Ken Lim Zhao Qi, Ethan Low Yu Jie and Constance Wong Poh Yin as directors of the Company. The initial term as director for each of the directors will expire at the Company’s 2024 annual meeting of stockholders. The Board deemed Messrs. Bonte, Chua and Lim as independent under the applicable standards of the Securities and Exchange Commission and Nasdaq. Messrs. Bonte, Chua and Lim were appointed to the Audit Committee and Compensation Committee of the Board with Mr. Lim serving as Chair of the Audit Committee and Mr. Chua serving as Chair of the Compensation Committee.

     

    The biographies of the newly appointed directors are set forth below.

     

    Christian-Laurent Bonte, age 47, is the owner of Far Cap Pte Ltd, a Singapore-based business founded by Mr. Bonte in December 2017, and which is engaged in corporate financing and investing transactions primarily focused on the technology industry. He served as Managing Director of Far Cap Pte Ltd from December 2021 to March 2024. Most recently, Mr. Bonte joined Meyzer Capital Management Pte Ltd, a management consulting and alternative investments platform, in March 2024 and, since July 2024, has served as Executive Director with responsibilities for fund management. From August 2017 to December 2021, Mr. Bonte served as Managing Director of ARC Capital Ltd, an investment bank focusing on middle market transactions with offices in Asia and the United States.

     

    Victor Chua Kok Hoe, age 36, is the Managing Partner and Founder of Vynn Capital, a venture capital firm investing in early-stage technology companies in the Asia Pacific that works alongside family offices and large institutions and companies in technology adoption and innovation. Vynn Capital is a partner of the United Nations World Tourism Organization that works with companies in the industries of travel mobility, property, food and fast-moving consumer goods or packaged goods. Prior to that, he was the Vice President of Investments for Gobi Partners, an early-to-late-stage venture capital firm where he managed two Southeast Asia-focused early-stage funds and a growth stage fund. Prior to that, he served with the venture capital arm of Malaysia’s Ministry of Finance where he managed direct and indirect investments. Some of the notable investments he supervised include Carsome (Malaysia), Travelio (Indonesia), Dropee, Triip.me (Vietnam), Hermo and Jirnexu.

     

    Earlier in his career, Mr. Chua worked for Willis Towers Watson, where he advised corporate, pension and sovereign wealth funds on investment strategies. He was an honoree of the Forbes Asia 30 under 30 in 2017. He is the Immediate Past Chairman of the Malaysia Venture Capital and Private Equity Association and a mentor with the Founder Institute and other grass-root entrepreneurial initiatives. Mr. Chua is also a Council Member of the Malaysian Venture Capital and Private Equity Development Council appointed by the Securities Commission of Malaysia. Mr. Chua was also a startup founder of an online education platform as well as two other businesses. He is a member of Mensa and a CFA charter holder.

     

    Ken Lim Zhao Qi, age 38, has served as Chief Executive Officer and Executive Director of the European Credit Investment Bank Ltd, a licensed midshore investment bank based in Labuan, Malaysia, since 2014. During his tenure, he has been responsible for substantial growth of the bank. Since 2023, he has served as the Chairman of the Labuan Investment Banking Association and has served on the board of Sentoria Group Berhad, a tourism resort and integrated travel destination operator listed on the Bursa Malaysia Stock Exchange. Mr. Lim received his Bachelor’s degree from the University Technology of Sydney.

     

    Ethan Low Yu Jie, age 35, is the Deputy President of Corporate Development and Portfolio Management for the AEI Capital Group, a growth equity investment firm, where he has served in such role since January 2024. He has worked for AEI Capital Group in various roles of increasing responsibility since 2016. Mr. Low’s responsibilities have included assisting the company’s chief executive officer in the company’s private equity investments and portfolio management activities, overseeing compliance matters and serving as a director for some of the company’s subsidiaries. Mr. Low was a practicing lawyer prior to joining AEI Capital Group. Mr. Low received his Bachelor of Laws degree from the University of Malaya.

     

    Constance Wong Poh Yin, age 34, is Senior Vice President of Group Operations and Business Development at AEI Capital Group, where she has served in that role since January 2024. Since 2016, she has held various roles of increasing importance at AEI Capital Group focusing on improving operational processes and supporting the company’s growth through business development strategies. Prior to that, Ms. Wong began her career as a practicing lawyer. Ms. Wong holds a Bachelor of Laws degree from the University of Malaya.

     

    1

     

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Number   Description
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: August 15, 2024 OpGen, Inc.
         
      By: /s/ John Tan Honjian
        Name: John Tan Honjian
        Title: Chief Executive Officer and Chairman

     

    3

    Get the next $OPGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPGN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OPGN
    SEC Filings

    View All

    OpGen Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CapForce Inc. (0001293818) (Filer)

    2/27/26 5:29:02 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form DEF 14A filed by OpGen Inc.

    DEF 14A - OPGEN INC (0001293818) (Filer)

    2/6/26 1:05:05 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form PRE 14A filed by OpGen Inc.

    PRE 14A - OPGEN INC (0001293818) (Filer)

    1/26/26 5:25:46 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Bonte Christian-Laurent claimed ownership of 28,571 shares (SEC Form 3)

    3 - OPGEN INC (0001293818) (Issuer)

    12/10/25 9:08:45 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Large owner Aei Capital Ltd bought $4,790 worth of shares (1,000 units at $4.79), increasing direct ownership by 0.01% to 7,646,603 units (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    7/30/25 2:04:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Chief Technology Officer (CTO) Syed Mohd Syed Johan Bin was granted 9,709 shares (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    4/30/25 4:32:10 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.

    CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OpGen, Inc. (OTC:OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in order to reflect the repositioning of the Company's business to the digital investment banking and financial technology sectors. The name "CapForce" represents the "Force of Capital," symbolizing the Company's conviction as a next-generation category-defining fintech-powered investment bank that harnesses the intrinsic force of capital, through capital markets as the empowerment medium, to empower global mid-sized high growth companies to grow beyond the small-cap universe and punch above their w

    2/27/26 5:30:32 PM ET
    $OPGN
    Medical Specialities
    Health Care

    OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q

    ROCKVILLE, Md., May 24, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) announced today that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the Company not filing its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the "Form 10-Q"), which serves as an additional basis for delisting the Company's securities from Nasdaq, and that the Nasdaq Hearings Panel will consider this matter in connection with the continued listing of the Company's securities on Nasdaq. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all

    5/24/24 4:04:59 PM ET
    $OPGN
    Medical Specialities
    Health Care

    OpGen Announced 1-for-10 Reverse Stock Split

    ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))) today announced that the Company's board of directors has approved a 1-for-10 reverse stock split of its shares of common stock (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. EST on May 20, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company's existing trading symbol "OPGN." The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 68373L505. OpGen expects that the Reverse Stock Split, which was approved by its stockholders at a Special

    5/16/24 7:00:00 AM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Aei Capital Ltd bought $4,790 worth of shares (1,000 units at $4.79), increasing direct ownership by 0.01% to 7,646,603 units (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    7/30/25 2:04:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Large owner Aei Capital Ltd bought $1,916,326,200,000 worth of shares (2,400,000 units at $798,469.25) (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    12/10/24 12:32:18 PM ET
    $OPGN
    Medical Specialities
    Health Care

    Large owner Aei Capital Ltd bought $11,130,140,980,409 worth of shares (5,245,603 units at $2,121,803.91) (SEC Form 4)

    4 - OPGEN INC (0001293818) (Issuer)

    10/8/24 6:51:09 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright resumed coverage on OpGen with a new price target

    HC Wainwright resumed coverage of OpGen with a rating of Buy and set a new price target of $4.00

    3/15/21 7:37:07 AM ET
    $OPGN
    Medical Specialities
    Health Care

    Alliance Global Partners reiterated coverage on OpGen with a new price target

    Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously

    3/8/21 8:22:12 AM ET
    $OPGN
    Medical Specialities
    Health Care

    Alliance Global Partners reiterated coverage on OpGen with a new price target

    Alliance Global Partners reiterated coverage of OpGen with a rating of Buy and set a new price target of $7.00 from $5.65 previously

    3/2/21 10:53:18 AM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by OpGen Inc.

    SC 13D/A - OPGEN INC (0001293818) (Subject)

    8/1/24 5:25:39 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by OpGen Inc. (Amendment)

    SC 13D/A - OPGEN INC (0001293818) (Subject)

    4/25/24 5:43:11 PM ET
    $OPGN
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by OpGen Inc. (Amendment)

    SC 13D/A - OPGEN INC (0001293818) (Subject)

    4/8/24 4:05:12 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $OPGN
    Financials

    Live finance-specific insights

    View All

    OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

    Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022Signed FIND R&D collaboration contract extensionEntered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S.Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ET ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 f

    8/10/23 4:15:00 PM ET
    $OPGN
    Medical Specialities
    Health Care

    OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time

    ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) ("OpGen" or "the Company") announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023. OpGen's management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide an update on business activities. Conference Call Details       U.S. Dial-in Number:   1-877-704-4453       International Dial-in Number: 1-201-389-0920      Webcast:   https://viavid.webcasts.com/starthere.jsp?ei=1618010&tp_key=fc7c8907d6  Re

    8/3/23 7:30:00 AM ET
    $OPGN
    Medical Specialities
    Health Care

    OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

    Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero UTI De Novo FDA submission and Unyvero distribution partnership with Fisher HealthcareMet all remaining key milestones of the FIND collaboration for Unyvero A30Management conference call scheduled for May 15, 2023, at 4:30 p.m. EST ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN, "OpGen" or "the Company"))), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its first quarter 20

    5/15/23 4:15:00 PM ET
    $OPGN
    Medical Specialities
    Health Care